- Section 1 The Subject Matter of and Approach to Psychiatry
- 1.3 Psychiatry as a worldwide public health problem
- 1.4 The history of psychiatry as a medical specialty
- 1.5 Ethics and values
- 1.6 The psychiatrist as a manager
- 1.7 Descriptive phenomenology
- 1.8 Assessment
- 1.9 Diagnosis and classification
- 1.10 From science to practice
- Section 2 The Scientific Basis of Psychiatric Aetiology
- 2.3 The contribution of neurosciences
- 2.4 The contribution of genetics
- 2.5 The contribution of psychological science
- 2.6 The contribution of social sciences
- 2.7 The contribution of epidemiology to psychiatric aetiology
- Section 3 Psychodynamic Contributions to Psychiatry
- Section 4 Clinical Syndromes of Adult Psychiatry
- 4.4 Persistent delusional symptoms and disorders
- 4.5 Mood disorders
- 4.6 Stress-related and adjustment disorders
- 4.7 Anxiety disorders
- Section 5 Psychiatry and Medicine
- Section 6 Treatment Methods in Psychiatry
- 6.2 Somatic treatments
- 6.2.1 General principles of drug therapy in psychiatry
- 6.2.2 Anxiolytics and hypnotics
- 6.2.3 Antidepressants
- 6.2.4 Lithium and related mood stabilizers
- 6.2.5 Antipsychotic and anticholinergic drugs
- 6.2.6 Antiepileptic drugs
- 6.2.7 Drugs for cognitive disorders
- 6.2.8 Drugs used in the treatment of the addictions
- 6.2.9 Complementary medicines
- 6.2.10 Non-pharmacological somatic treatments
- 6.3 Psychological treatments
- 6.4 Treatment by other professions
- 6.5 Indigenous, folk healing practices
- Section 7 Social Psychiatry and Service Provision
- Section 8 The Psychiatry of Old Age
- Section 9 Child and Adolescent Psychiatry
Antipsychotic and anticholinergic drugs
- Chapter:
- Antipsychotic and anticholinergic drugs
- Author(s):
Herbert Y. Meltzer
and William V. Bobo
- DOI:
- 10.1093/med/9780199696758.003.0155
The discovery by Delay and Denicker in 1953 that chlorpromazine was highly effective in alleviating delusions, hallucinations, and disorganized thinking, was the seminal breakthrough in the treatment of schizophrenia, the first agent to produce sufficient relief of core psychotic symptoms to permit life outside of institutions for many patients with schizophrenia, and even a return to a semblance of function within normal limits. Chlorpromazine and the other related typical antipsychotic drugs which were introduced over the next 30 years have proven to be of immense benefit to vast numbers of people who experience psychotic symptoms as a component of a diverse group of neuropsychiatric and medical disorders, as well as drug-induced psychoses. These drugs have been invaluable in providing clues to the aetiology of schizophrenia and other forms of mental illness with psychotic features and as tools in understanding fundamental neural processes, especially those involving dopamine, a key neurotransmitter involved in psychosis. This class of drugs has now been supplanted by the so-called atypical antipsychotic drugs, of which clozapine is the prototype. This chapter will describe the various classes of antipsychotic agents, with emphasis on the atypical antipsychotic drugs, their benefits and adverse effects, recommendations for use in clinical practice, and mechanism of action. The drugs used to treat the extrapyramidal side-effects (EPS) produced mainly by the typical antipsychotic drugs are also considered.
Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.
Please subscribe or login to access full text content.
If you have purchased a print title that contains an access token, please see the token for information about how to register your code.
For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.
- Section 1 The Subject Matter of and Approach to Psychiatry
- 1.3 Psychiatry as a worldwide public health problem
- 1.4 The history of psychiatry as a medical specialty
- 1.5 Ethics and values
- 1.6 The psychiatrist as a manager
- 1.7 Descriptive phenomenology
- 1.8 Assessment
- 1.9 Diagnosis and classification
- 1.10 From science to practice
- Section 2 The Scientific Basis of Psychiatric Aetiology
- 2.3 The contribution of neurosciences
- 2.4 The contribution of genetics
- 2.5 The contribution of psychological science
- 2.6 The contribution of social sciences
- 2.7 The contribution of epidemiology to psychiatric aetiology
- Section 3 Psychodynamic Contributions to Psychiatry
- Section 4 Clinical Syndromes of Adult Psychiatry
- 4.4 Persistent delusional symptoms and disorders
- 4.5 Mood disorders
- 4.6 Stress-related and adjustment disorders
- 4.7 Anxiety disorders
- Section 5 Psychiatry and Medicine
- Section 6 Treatment Methods in Psychiatry
- 6.2 Somatic treatments
- 6.2.1 General principles of drug therapy in psychiatry
- 6.2.2 Anxiolytics and hypnotics
- 6.2.3 Antidepressants
- 6.2.4 Lithium and related mood stabilizers
- 6.2.5 Antipsychotic and anticholinergic drugs
- 6.2.6 Antiepileptic drugs
- 6.2.7 Drugs for cognitive disorders
- 6.2.8 Drugs used in the treatment of the addictions
- 6.2.9 Complementary medicines
- 6.2.10 Non-pharmacological somatic treatments
- 6.3 Psychological treatments
- 6.4 Treatment by other professions
- 6.5 Indigenous, folk healing practices
- Section 7 Social Psychiatry and Service Provision
- Section 8 The Psychiatry of Old Age
- Section 9 Child and Adolescent Psychiatry